← All organizations
Highest phase reached
Phase 4
First clinical trial
May 1, 2006First marketed drug
Jun 23, 2017First NDA
Jun 23, 2017Last known activity
Dec 13, 2019
Acquired by Alexion → AstraZeneca on May 4, 2020
Timeline
2000s
- Jul 1, 2003
Portola Pharmaceuticals— Founded
2010s
- Jun 23, 2017
betrixaban— NDA Organization
- Jun 23, 2017
betrixaban— NDA Secondary Org
2020s
- May 4, 2020
Alexion— Acquired By
- Oct 13, 2020
AstraZeneca— Now
Drugs by trial phase (11 distinct, 28 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Indications
Approved for
Studied for
- Atrial Fibrillation
- Atrial Flutter
- Hemorrhage
- Infarction
- Intracranial Hemorrhages
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Liver Diseases
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Myocardial Infarction
- Renal Insufficiency
- Thromboembolism
- Venous Thromboembolism
Marketed drugs (1)
Recent trials (32)
- NCT04233073Lead sponsorPhase 3Dec 13, 2019
- NCT04021082Lead sponsorPhase 2/Phase 3Aug 1, 2019
- NCT03661528Lead sponsorPhase 4Jan 1, 2019
- NCT03346083Lead sponsorPhase 1Jul 18, 2018
- NCT03397888Lead sponsorPhase 1Nov 16, 2017
- NCT03310021Lead sponsorPhase 2Aug 28, 2017
- NCT03083704Lead sponsorPhase 1Feb 26, 2017
- NCT02596100Lead sponsorPhase 1Sep 1, 2015
- NCT03330457Lead sponsorPhase 2Aug 30, 2015
- NCT02329327Lead sponsorPhase 3Jan 1, 2015
- NCT02220725Study directorPhase 3May 1, 2014
- NCT02220725Lead sponsorPhase 3May 1, 2014
- NCT02207725Study directorPhase 3Mar 1, 2014
- NCT02207725Lead sponsorPhase 3Mar 1, 2014
- NCT01994382Lead sponsorPhase 1/Phase 2Aug 1, 2013
Details
- Founded
- South San Francisco, CA, US Jul 1, 2003
- First NDA
- Jun 23, 2017
- Last known activity
- Dec 13, 2019
Designations held
- Fast track
- Priority review